Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date
Open Access
- 1 October 2016
- journal article
- review article
- Published by Taylor & Francis in HIV/AIDS - Research and Palliative Care
- Vol. ume 8, 157-164
Abstract
Modern antiretroviral therapy has demonstrated effectiveness in preexposure prophylaxis (PrEP) and treatment of HIV infection. There is a demand for prevention and treatment regimens that could overcome challenges of improving adherence, toxicity, and dosing convenience. Cabotegravir is an integrase strand transfer inhibitor and an analog of dolutegravir. Unlike dolutegravir, cabotegravir has a long half-life and can be formulated into a long-acting nanosuspension for parenteral administration. Initial pharmokinetic studies in humans have demonstrated adequate drug levels with intramuscular (IM) administration at 4 weekly and 8 weekly intervals, with few interactions with commonly used concomitant medications. Preliminary animal PrEP studies have shown that IM cabotegravir can prevent simian/HIV acquisition from rectal, vaginal, and intravenous challenge. Currently, there are two ongoing Phase II studies assessing cabotegravir as a PrEP agent in humans: ÉCLAIR and HPTN077. Cabotegravir has been studied in combination with rilpivirine as long-acting IM maintenance therapy. The Long-Acting Antiretroviral Treatment Enabling study demonstrated that those switching to oral cabotegravir/rilpivirine once virologically suppressed were more likely to maintain suppression than those continuing standard efavirenz-based therapy (82% vs 71% at 24 weeks). Initial results of the Long-Acting Antiretroviral Treatment Enabling-2 study of parenteral regimens found that 12 weeks after randomization to parenteral or oral regimens, there was no difference in proportions virologically suppressed on cabotegravir/rilpivirine daily orally vs IM every 4 weeks or 8 weeks (91% vs 94% vs 95%). The injections were well tolerated as, although they caused injection site pain in most recipients, most participants reported satisfaction with parenteral therapy. Cabotegravir offers a new member of the integrase strand transfer inhibitor class with potential for alternative mode of delivery. We await Phase III studies to define its efficacy and real-world experience to learn which patient groups stand to benefit most from the novel mode of delivery of treatment and PrEP.Keywords
This publication has 41 references indexed in Scilit:
- Tenofovir and bone healthCurrent Opinion in HIV and AIDS, 2016
- Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trialThe Lancet, 2016
- Meta-Analysis of Studies Comparing Single and Multi-Tablet Fixed Dose Combination HIV Treatment RegimensMedicine, 2015
- Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trialThe Lancet Infectious Diseases, 2015
- Initiation of Antiretroviral Therapy in Early Asymptomatic HIV InfectionNew England Journal of Medicine, 2015
- Antiviral Characteristics of GSK1265744, an HIV Integrase Inhibitor Dosed Orally or by Long-Acting InjectionAntimicrobial Agents and Chemotherapy, 2015
- Prevention of Vaginal SHIV Transmission in Macaques by a Coitally-Dependent Truvada RegimenPLOS ONE, 2012
- Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in BotswanaNew England Journal of Medicine, 2012
- Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and WomenNew England Journal of Medicine, 2012
- Preexposure Prophylaxis for HIV Infection among African WomenNew England Journal of Medicine, 2012